Key result
Gene therapy affecting potassium channels represents a highly promising approach for the treatment of pharmacoresistant focal epilepsy.
Why the study?
K+ channels control neuronal intrinsic excitability and mutations in their genes are linked to inherited epilepsy, making them targets for drugs and gene therapy.
Highlights the potential of targeting potassium channels, particularly through gene therapy, for treating pharmacoresistant focal epilepsy.
Answers are grounded in this paper and cite their sources.
May offer a future option in pharmacoresistant focal epilepsy; hypothesis-generating and requires prospective trials before clinical adoption.
Introduction K+ channels are of great interest to epilepsy research as mutations in their genes are found in humans with inherited epilepsy. At the level of cellular physiology, K+ channels control neuronal intrinsic excitability and are the main contributors to membrane repolarization of active neurons. Recently, a genetically modified voltage-dependent K+ channel has been patented as a remedy for epileptic seizures.Areas covered We review the role of potassium channels in excitability, clinical and experimental evidence for the association of potassium channelopathies with epilepsy, the targeting of K+ channels by drugs, and perspectives of gene therapy in epilepsy with the expression of extra K+ channels in the brain.Expert Opinion Control over K+ conductance is of great potential benefit for the treatment of epilepsy. Nowadays, gene therapy affecting K+ channels is one of the most promising approaches to treat pharmacoresistant focal epilepsy.
No takes yet. Share an insight, caveat, or question.
Никитин et al. (2021) conducted a review in Epilepsy. Potassium channel targeting and gene therapy was evaluated. Gene therapy affecting potassium channels represents a highly promising approach for the treatment of pharmacoresistant focal epilepsy.
Synapse has enriched 10 related papers. Consider them for comparative context: